Equities

SCI Pharmtech Inc

4119:TAI

SCI Pharmtech Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (TWD)97.50
  • Today's Change-0.50 / -0.51%
  • Shares traded280.20k
  • 1 Year change+8.70%
  • Beta--
Data delayed at least 20 minutes, as of Nov 22 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of TWD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments1,031264693
Total Receivables, Net308205349
Total Inventory530513294
Prepaid expenses------
Other current assets, total856062
Total current assets1,9531,0421,397
Property, plant & equipment, net3,9123,1942,100
Goodwill, net------
Intangibles, net465560
Long term investments470436125
Note receivable - long term------
Other long term assets15766266
Total assets6,6914,9614,190
LIABILITIES
Accounts payable444934
Accrued expenses828578
Notes payable/short-term debt1751120
Current portion long-term debt/capital leases220.831.58
Other current liabilities, total247524635
Total current liabilities570770748
Total long term debt8464330.57
Total debt1,0425452.16
Deferred income tax146104104
Minority interest------
Other liabilities, total292517
Total liabilities1,5911,331869
SHAREHOLDERS EQUITY
Common stock1,195954954
Additional paid-in capital2,2341,3571,348
Retained earnings (accumulated deficit)1,6461,3731,067
Treasury stock - common------
Unrealized gain (loss)25(55)(49)
Other equity, total------
Total equity5,1003,6293,321
Total liabilities & shareholders' equity6,6914,9614,190
Total common shares outstanding120109109
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.